Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by ElMaestro  – Belgium?, 2019-04-03 13:22  – Posting: # 20118
Views: 803

Hi sury,

» Can anyone have any idea how can we provide sample size for the PD endpopints

The overarching principle is the same:
You need to guesstimate the resemblance along with the variability of the quantity on which equivalence is determined. The first one is entirely formulation dependent, the latter is biological in nature.
In consequence you first decide on the design and the stats model, and then you work out the sample size from that model.

You will need to be very, very specific in order for anyone here to help you with the actual sample size. Very often you will not find info in the public domain that can be used to calculate sample size (like variability for certain nasal and inhalation drug PD endpoints). In those cases where you can't look up variability in literature/FOI act access/journals/etc you will not get a qualified sample size without at least a pilot study.
Note also that for FDA some PD endpoints are complex in that superiority to placebo is required along with proof of equivalence for T vs R. This is not always entirely straightforward.

I could be wrong, but...
Best regards,
ElMaestro

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,687 posts in 4,178 threads, 1,352 registered users;
online 10 (0 registered, 10 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 20:45 CEST

The fundamental cause of trouble in the world today is
that the stupid are cocksure
while the intelligent are full of doubt.    Bertrand Russell

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5